{"product_id":"sirukumab-elisa-kit-bhe21400350","title":"Sirukumab ELISA Kit","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\u003cp\u003e\u003cstrong\u003eSirukumab ELISA Kit\u003c\/strong\u003e is an ELISA-based immunoassay designed for quantitative measurement of \u003cstrong\u003eSirukumab\u003c\/strong\u003e in research samples. It is commonly used to generate traceable concentration data for biomarker discovery, pathway studies, and comparative analyses across experimental conditions.\u003c\/p\u003e\u003ch2\u003eKey elements and design rationale\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eAssay format:\u003c\/strong\u003e Quantitative Colorimetric ELISA. The format defines how signal scales with analyte abundance and how results are interpreted across a standard curve.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eWorking range and sensitivity:\u003c\/strong\u003e dynamic range 0.31-5 μg\/mL; analytical sensitivity 0.156 μg\/ml. Use these values to plan dilutions and keep readouts within the linear portion of the calibration curve.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSample compatibility:\u003c\/strong\u003e Intended for Plasma, Serum matrices. As with most immunoassays, matrix composition can influence apparent signal and should be evaluated with dilution linearity and spike-recovery concepts.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eRecovery reference:\u003c\/strong\u003e Typical recovery is reported as 80-120%. Recovery helps assess whether the sample matrix interferes with detection of spiked analyte.\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp\u003eThis kit is supplied for research use in laboratory settings where defined, quantitative readouts are needed for experimental interpretation.\u003c\/p\u003e\u003ch2\u003eBiological background\u003c\/h2\u003e\u003cp\u003eSirukumab (developmental code name CNTO-136) is a human monoclonal antibody (mAb) designed for the treatment of rheumatoid arthritis (RA). It acts against the proinflammatory cytokine interleukin (IL) -6 (IL-6). Sirukumab was evaluated in five Phase 3 studies of patients with RA. In September 2016, Janssen submitted a biologics license application (BLA) seeking approval of sirukumab for the treatment of moderately to severely active RA, but they announced in September 2017 that they received a complete response letter from the Food and Drug Administration (FDA) indicating additional clinical data were needed to further evaluate the safety of sirukumab in that patient population. Janssen subsequently decided not to pursue global approvals of sirukumab for the treatment of moderately to severely active RA. Sirukumab was being evaluated in a Phase 3 study (NCT02531633) of another inflammatory disease, giant cell arteritis. This study, sponsored by GlaxoSmithKline (GSK), was terminated in November 2017 due to GSK’s decision to return rights to sirukumab to Janssen and discontinue sirukumab development in giant cell arteritis. Also, in November 2017, a Phase 3 study (NCT02899026) sponsored by GSK of sirukumab in patients with polymyalgia rheumatica, an inflammatory disorder that causes muscle pain and stiffness, was withdrawn prior to enrollment.\u003c\/p\u003e\u003ch2\u003eResearch relevance and current trends\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eBiomarker translation in RUO settings:\u003c\/strong\u003e Increasing use of quantitative immunoassays to stratify experimental cohorts, track longitudinal changes, and benchmark model systems.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMatrix-aware assay design:\u003c\/strong\u003e Greater emphasis on dilution linearity, spike-recovery, and control concepts to reduce matrix-driven artifacts in serum\/plasma and complex lysates.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eIntegration with multi-omics:\u003c\/strong\u003e ELISA measurements are often used alongside transcriptomics and proteomics to connect abundance changes with pathway activity and phenotype.\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eCommon research applications\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eComparative quantification:\u003c\/strong\u003e Measure relative changes in analyte levels across treatments, time points, or genotypes to support mechanistic hypotheses.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eAssay development and standardization:\u003c\/strong\u003e Generate reproducible concentration inputs for method qualification, inter-operator comparisons, or bridging studies across platforms.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eModel and sample characterization:\u003c\/strong\u003e Profile baseline and stimulated levels to help interpret immune, endocrine, neurodegenerative, or metabolic phenotypes (as relevant to the target).\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp\u003eInterpretation typically focuses on direction and magnitude of change in the context of controls and sample handling metadata, rather than single-point absolute values.\u003c\/p\u003e\u003ch2\u003eNotes for experimental interpretation\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eMatrix effects:\u003c\/strong\u003e Hemolysis, lipemia, and high protein content can alter background and apparent concentration. Consider consistent collection\/processing and evaluate dilution behavior.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eIsoforms and modified forms:\u003c\/strong\u003e Some targets exist as isoforms, fragments, or post-translationally modified species. Ensure the measured form aligns with the biological question and the kit’s intended analyte definition.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eControl concepts:\u003c\/strong\u003e Use negative\/blank controls, replicate wells, and—when feasible—orthogonal confirmation (e.g., WB or MS) to strengthen conclusions.\u003c\/li\u003e\n\u003c\/ul\u003e\u003c!-- Sources (internal): - UniProt (search): https:\/\/www.uniprot.org\/uniprotkb?query=Sirukumab - NCBI Gene (search): https:\/\/www.ncbi.nlm.nih.gov\/gene\/?term=Sirukumab - Ensembl (search): https:\/\/www.ensembl.org\/Multi\/Search\/Results?q=Sirukumab - PubMed (search): https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=Sirukumab - NCBI Bookshelf (background reviews): https:\/\/www.ncbi.nlm.nih.gov\/books\/?term=Sirukumab --\u003e","brand":"Biohippo Inc","offers":[{"title":"96 T","offer_id":53047354917229,"sku":"DY328038-96T","price":1126.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/ELISA_Kits_Display_Image_1_0f99794a-5747-4c36-a640-50cbb7ca13f5.png?v=1772020768","url":"https:\/\/www.ebiohippo.com\/products\/sirukumab-elisa-kit-bhe21400350","provider":"BioHippo","version":"1.0","type":"link"}